Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$27.32 -0.91%

-$0.33 today

Market cap
$1.39B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.18M

Average 0.08M

Income Statement

Follow revenue through to earnings.

Revenue

$29.64M

FY 2025 · Annual

Operating Income

-$10.82M

FY 2025 · Annual

Net Income

-$23.96M

FY 2025 · Annual

Income Statement

EUR
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

NBTX Earnings Waterfall · TTM

NASDAQ:NBTX · Revenue to Net Income

Key Ratios

EPS$-1.94
Gross Margin100.0%
Net Margin-148.3%
P/E Ratio-6.2
P/S Ratio84.4

Analysis

$22.5M of revenue converted into -$92.1M of net income for the selected period. Gross margin is 100.0% and net margin is -148.3%, showing how much revenue survives after costs and taxes. EPS is $-1.94, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 9, 2026
6-K6-K filingOct 26, 2026
6-K6-K filingOct 20, 2026
6-K6-K filingOct 1, 2026

How much revenue does NBTX generate?

Nanobiotix S.A. (NBTX) reported $29.64M of revenue in fiscal 2025.

Is NBTX profitable?

Nanobiotix S.A. (NBTX) reported -$23.96M of net income, with a net margin of -80.8%.